Prudential Financial’s Bolt Biotherapeutics BOLT Stock Holding History

Prudential Financial’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,960	Closed	-$38.4K	–	2329
2024 Q3	$38.4K	Buy	2,960 +240	+9%	+$3.31K	﹤0.01%	2666
2024 Q2	$40.8K	Buy	2,720 +960	+55%	+$18.9K	﹤0.01%	2632
2024 Q1	$49.3K	Buy	1,760 +1,150	+189%	+$26.6K	﹤0.01%	2592
2023 Q4	$13.7K	Buy	+610	New	+$11.9K	﹤0.01%	2630
2023 Q3	–	Sell	-1,220	Closed	-$31.2K	–	2607
2023 Q2	$31.2K	Hold	1,220	–	–	﹤0.01%	2581
2023 Q1	$33.9K	Hold	1,220	–	–	﹤0.01%	2533
2022 Q4	$31.7K	Buy	1,220 +410	+51%	+$11.2K	﹤0.01%	2537
2022 Q3	$24K	Hold	810	–	–	﹤0.01%	2621
2022 Q2	$33K	Buy	+810	New	+$31.4K	﹤0.01%	2606
2021 Q3	–	Sell	-1,005	Closed	-$311K	–	2591
2021 Q2	$311K	Buy	+1,005	New	+$408K	﹤0.01%	2294

Other funds holding BOLT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential Financial's BOLT Position: Q4 2024 in Review

Prudential Financial sold out of Bolt Biotherapeutics (BOLT) in Q4 2024, closing a stake of 2,960 shares — an estimated $38.4K sold.

Prudential Financial first reported a position in BOLT in Q2 2021 and held it in 10 quarters. The position peaked at $311K in Q2 2021. 37 funds tracked by Wall St. Rank hold BOLT as of Q4 2024.

Prudential Financial reported no remaining Bolt Biotherapeutics position as of Q4 2024 after selling out during the quarter.
Prudential Financial sold 2,960 Bolt Biotherapeutics shares in Q4 2024, an estimated $38.4K.
Prudential Financial first reported a position in Bolt Biotherapeutics in Q2 2021 and held it in 10 quarters.
Prudential Financial's Bolt Biotherapeutics position peaked at $311K in Q2 2021.
37 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2024.

Based on Prudential Financial's 13F filing for Q4 2024, filed 11 Feb 2025.